Agios Pharmaceuticals, Inc. (AGIO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 14 | 27 | 36 | 54 | 98 | 183 |
| Operating profit | $m | -472 | -459 | ||||||
| Net profit | $m | -327 | 1,605 | -232 | -352 | 674 | -413 | -411 | -336 |
| EPS reported | $ | -7.12 | -7.01 | ||||||
| Operating cashflow per share | $ | -6.43 | -6.06 | ||||||
| Capex per share | $ | 0.07 | 0.08 | ||||||
| FCF per share | $ | -6.51 | -6.14 | ||||||
| Free cash flow | $m | -377 | -365 | ||||||
| Net debt | $m | -854 | -618 | ||||||
| Book value equity | $m | 1,193 | 1,026 | ||||||
| Book value per share | $ | 20.58 | 17.25 | ||||||
| Number of shares | m | 57.97 | 59.49 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.32 | 1.54 | ||||||
| P/S LTM | x | 29.21 | 16.05 | ||||||
| P/FCF LTM | x | -4.18 | -4.32 | ||||||
| EV/EBITDA LTM | x | -3.74 | -3.67 | ||||||
| EV/Sales LTM | x | 28.30 | 19.40 | ||||||
| Earnings Yield LTM | % | -26.16% | -20.89% | ||||||
| FCF Yield | % | -23.91% | -23.15% | ||||||
| Quality | |||||||||
| ROE | % | -34.60% | -35.67% | ||||||
| ROIC | % | -38.18% | -43.30% | ||||||
| Operating margin | % | -8.74% | -4.67% | ||||||
| Gross margin | % | +78.67% | +87.92% | ||||||
| FCF/Sales | % | -698.33% | -371.43% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +48.03% | +169.43% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -9.38 | -11.72 | ||||||
| Net Debt/EBITDA | x | 0.12 | 0.16 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.72 | -0.60 | ||||||
| Gross debt/equity | x | 0.03 | 0.03 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Agios Pharmaceuticals, Inc. (AGIO)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free